Expression and clinical significance of IMP3 and p16 in cervical carcinoma

Abstract

Abstract:ObjectiveTo detect the expression of insulinlike growth factor Ⅱ mRNAbinding protein 3 (IMP3) and p16 in cervical carcinoma and investigate their clinical significance. MethodsImmunohistochemical Envision method was used to detect the expression of IMP3 and p16 proteins in 67 cases of carcinoma of the uterine cervix, 58 cases of cervical intraepithelial neoplasia (CIN) and 15 cases of normal cervical epithelium. ResultsIMP3 was mainly dedected in the cytoplasm, whose positive expression rate was 85.07%（57/67）in cervical carcinoma, 12.07% (7/58) in CIN (χ2=66.32, P＜0.05) and 0 (0/15) in cervical epithelium (χ2=44.38, P＜0.05). No significance variations of the expression of IMP3 were observed in cervical adenocarcinoma and squamous cell carcinoma (χ2=0.35, P＞0.05). p16 was found both in nucleus and cytoplasm of cervical carcinoma, whose expression rate was 83.58% (56/67), higher than 41.37% (24/58) in CIN (χ2=24.85, P＜0.05) and 0 (0/15) in cervical epithelium (χ2=42.61, P＜0.05). ConclusionExpression of IMP3 and p16 is high in cervical carcinoma, maybe can be used as a potential biomarker of metastasis and progression.

Key words:Genes, p16,Uterine cervical neoplasms,Insulin-like growth factor Ⅱ mRNA-binding protein 3

FENG Yan-Li. Expression and clinical significance of IMP3 and p16 in cervical carcinoma[J]. Journal of International Oncology, 2014, 41(12): 946-949.

References

［1］ Parkin DM. The global health burden of infectionassociated cancers in the year 2002［J］. Int J Cancer, 2006, 118(12):30303044. ［2］董岩, 程静新, 宫颈癌及宫颈上皮内瘤变相关危险因素分析［D］. 新疆, 新疆医科大学. 2010:1213. ［3］ Wagner M, Kunsch S, Duerschmied D, et al. Transgenic over expression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas［J］. Gastroenterology, 2003, 124(7): 19011914. ［4］ Lu D, Yang X, Jiang NY, et al. IMP3, a new biomarker to predict progressi on of cervical intraepithelial neoplasiain to invasive cancer［J］. Am J Surg Pathol, 2011, 35(11): 16381645．［5］ Subhawong AP, Subhawong T, Nassar H, et al. Most basallike breast carcinomas demonstrate the same Rb-/pl6+ immunophenotype as the HPVrelated poorly differentiated squamous cell carcinomas which they resemble morphologically［J］. Am J Surg Pathol, 2009, 33(2): 163175. ［6］ Zushi Y, NarisawaSaito M, Noguchi K, et al. An in vitro multistep carcinogenesis modelfor both HPVpositive and negative human oral squamous cell carcinomas［J］. Am J Cancer Res, 2011, 1(7):869881. ［7］ Zheng T, Holford TR, Ma Z, et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon［J］. Epidemiology, 1996, 25(2): 252258. ［8］ Slosar M, Vohra P, Prasad M, et al. Insulinlike growth factor Mrna binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors［J］. Endocr Pathol, 2009, 20(3):149157. ［9］ Walter O, Prasad M, Lu S, et al. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype［J］. Hum Pathol, 2009, 40(11): 15281533. ［10］ Noske A, Faggad A, Wirtz R, et al. IMP3 expression in human ovarian cancer is associated with improved survival［J］. Int J Gynecol Pathol, 2009, 28(3): 203210. ［11］ Vikesaa J, Hansen TV, Jonson L, et al. RNAbinding IMPs promote celladhesion and in vadopodia formation［J］. Embo J, 2006, 25(7): 14561468. ［12］杨会杰, 宋金凤. IMP3、p53在宫颈癌中的表达及临床意义. 现代妇产科进展［J］. 2013, 22(4): 320324. ［13］武海英, 魏利, 史惠蓉. P16及pRb在宫颈癌中的表达及意义［J］. 中华实用诊断与治疗杂志, 2011, 25(10): 976978.

[1]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[2]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[3]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[4]	Ma Xueyan, Lu Lili, Sun Pengfei.Advances in the immune microenvironment in cervical cancer[J]. Journal of International Oncology, 2023, 50(1): 47-50.
[5]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[6]	Shi Yingxia, Hu Lijun, Yu Jingping.Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 568-571.
[7]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng.Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.
[8]	Yuan Chenyang, Zhou Juying.Research progress on prognostic factors of cervical cancer[J]. Journal of International Oncology, 2022, 49(5): 307-313.
[9]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting.Screening and treatment progression of elderly cervical cancer[J]. Journal of International Oncology, 2022, 49(12): 754-758.
[10]	Ma Xiuzhen, Lu Yan, Zhao Bingbing, Qiu Hongcong, Xu Xun, Wei Min.Effects of total flavonoids from Baeckea frutescens on the migration, invasion and apoptosis of cervical cancer SiHa cells[J]. Journal of International Oncology, 2021, 48(4): 206-211.
[11]	Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong.Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model[J]. Journal of International Oncology, 2021, 48(1): 35-40.
[12]	Ding Xuchao, Cao Lili.Common active targeting nano drug delivery systems for cervical cancer[J]. Journal of International Oncology, 2021, 48(1): 61-64.
[13]	Shu Hang, Xu Zhonghua, Zhu Haochen, Yang Yahui, Lyu Yin.Research progress of radiosensitivity in cervical cancer[J]. Journal of International Oncology, 2020, 47(8): 496-500.
[14]	Song Mingze, Cheng Yiming, Li Gang, Wang Zhenming, Li Shirong.Value of P16/Ki-67 double staining detection in screening cervical cancer and precancerous lesions[J]. Journal of International Oncology, 2020, 47(11): 675-681.
[15]	Li Ang, Wei Fang.Current status and future challenges of HPV preventive vaccine of cervical cancer[J]. Journal of International Oncology, 2019, 46(5): 307-310.